Clinical Research Directory

Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and lifestyle considerations and availability for the duration of the study * Non-recurrent non-fulminant CDI (laboratory-confirmed C. difficile infection without prior C. difficile infection within 3 months and no shock, hypotension, ileus, or megacolon) * Currently receiving treatment or with plan to initiate treatment for CDI * CDI treatment with standard regimen (fidaxomicin 200milligrams (mg) by mouth (PO) twice a day x 10-14 days or vancomycin 125mg PO 4 x a day (QID) x 10-14 days) * No prior advanced therapy for C. difficile (i.e. prolonged antibiotic therapy, bezlotoxumab, fecal transplant, other microbial therapy) Exclusion Criteria: * Chemotherapy, immunotherapy, or transplant within 12 months * Colon not in continuity (i.e. status post total colectomy or with current ileostomy) * Medical comorbidities requiring specific fluid, sodium, or protein intake level outside range of prepared diet options * Baseline diet with \> 11grams fiber/1000 kilocalories * Low sodium diet, vegan diet, gluten-free diet, Kosher diet or any other diet not able to be accommodated by the metabolic kitchen * Allergies, food preferences, or other restrictions not able to be accommodated by the metabolic (note: lactose intolerance will not impact eligibility) * Unwilling to stop probiotic supplements during the study period * Current antibiotic therapy that will continue after CDI treatment has finished * Hospitalized or in skilled nursing facility at time of CDI treatment conclusion * Pregnancy or breast-feeding * Unable to provide a stool sample of appropriate quality for further analysis (i.e. low volume, adulterated, delayed return, etc.)